S48-02 Drug interactions with antidementia drugs: Clinical consequences - 17/03/09
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 1 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Alzheimer" disease (AD) is a major public health problem, and it is at the origin of a significant burden: 15% of direct costs in dementia are attributed to pharmacological treatment. Persons with dementia often have comorbidities and receive multiple medications. Both factors increase the risk of drug-drug interactions (DDIs) which can result in adverse drug reactions (ADRs). In a study, a total of 1058 spontaneous reports were identified that involved cholinesterase inhibitors (ChEIs) in the French Pharmacovigilance Database; 35.5% contained at least one DDI; 118 of them (31.4%) were the cause of ADRs. Pharmacodynamic interactions play a far greater role than pharmacokinetic interactions in the significance of DDIs. Some known interactions with ChEIs are:
1. | atropinic drugs aggravate cognitive disorders; |
2. | combinations of ChEIs and antipsychotics are associated with an increased risk of extrapyramidal adverse effects; |
3. | combining ChEIs with drugs that reduce the heart rate, depress cardiac conduction, or induce torsades de pointes increases the risk of arrhythmias and cardiac conduction disorders. |
Vol 24 - N° S1
P. S243 - 2009 Retour au numéro
Article précédent
- S48-01 Risks of delirium in polymedicated elderly patients
- G. Stoppe
- S48-03 Polymedication in elderly psychiatric patients suffering from comorbidities: Risks for pharmacokinetic interactions with clinical consequences
- P. Baumann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?